Ondine Messeant
Overview
Explore the profile of Ondine Messeant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
2
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benguerfi S, Messeant O, Painvin B, Camus C, Maamar A, Gacouin A, et al.
Ann Intensive Care
. 2024 Aug;
14(1):135.
PMID: 39215851
Background: Post-intensive care syndrome could be responsible for inability to receive proper cancer treatment after ICU stay in patients with solid tumors (ST). Our purpose was to determine the factors...
2.
Messeant O, Drieux F, Sako N, Fataccioli V, Camus V, Robe C, et al.
Eur J Cancer
. 2023 Dec;
197:113479.
PMID: 38128263
Introduction: Follicular helper T-cell lymphomas (TFHL) have an aggressive course with a poor outcome. European and US guidelines recommend anthracycline-based chemotherapy as a first-line treatment, but the 5-year overall survival...
3.
4.
Messeant O, Houot R
Bull Cancer
. 2021 Dec;
108(10S):S28-S39.
PMID: 34920805
Three CD19 CAR-T cells (Yescarta®, Kymriah® and Breyanzi®), have been approved in relapsed or refractory diffuse large B cell lymphomas (DLBCL) after at least two previous lines of therapy. These...
5.
Messeant O, Houot R, Manson G
Cancers (Basel)
. 2021 Sep;
13(17).
PMID: 34503084
T-cell specificity can be redirected against tumor antigens either ex vivo using engineered chimeric antigen receptor (CAR) T-cells or in vivo by bridging natural T-cells and tumor cells with bispecific...